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In this work, we aimed to understand the biological activity and the mechanism of action of three
polymer-‘ruthenium-cyclopentadienyl’ conjugates (RuPMC) and a low molecular weight parental com-
pound (Ru1) in cancer cells. Several biological assays were performed in ovarian (A2780) and breast
(MCF7, MDA-MB-231) human cancer derived cell lines as well as in A2780cis, a cisplatin resistant cancer
cell line. Our results show that all compounds have high activity towards cancer cells with low IC50
values in the micromolar range. We observed that all Ru-PMC compounds are mainly found inside the
cells, in contrast with the parental low molecular weight compound Ru1 that was mainly found at the
membrane. All compounds induced mitochondrial alterations. PMC3 and Ru1 caused F-actin cytoskel-
eton morphology changes and reduced the clonogenic ability of the cells. The conjugate PMC3 induced
apoptosis at low concentrations comparing to cisplatin and could overcame the platinum resistance of
A2780cis cancer cells. A proteomic analysis showed that these compounds induce alterations in several
cellular proteins which are related to the phenotypic disorders induced by them.
Our results suggest that PMC3 is foreseen as a lead candidate to future studies and acting through a
different mechanism of action than cisplatin. Here we established the potential of these Ru compounds
as new metallodrugs for cancer chemotherapy.
© 2019 Elsevier Masson SAS. All rights reserved.1. Introduction
Chemotherapy is one of the basis of cancer therapy although theserved.drugs in clinical use present major limitations such as non-
selectivity and resistance to therapy which are responsible for
serious side effects. In this frame, several new approaches aiming
targeted therapy have been developed in the last years taking
advantage of the specific characteristics of cancer cells, such as the
permeability to macromolecules, acidic extracellular pH, overex-
pressed cell surface receptors, among others. In the case of
T. Moreira et al. / European Journal of Medicinal Chemistry 168 (2019) 373e384374platinum-based drugs, some of the approaches include the conju-
gation of platinum drugs with peptides [1e6], receptor-specific li-
gands [4,7], or polymers [1,8e11], the formulation of nanoparticles
[8e10,12e14], or photosensitizers [11], to name a few. Peptides, and
receptor-specific ligands conjugates can be used for active target-
ing, while polymers and nanoparticles are usually applied for
passive targeting. Photosensitizers are typically used in photody-
namic therapy. The research in this area is very active and the data
obtained so far is promising. However, even after many years of
development, platinum based anticancer drugs still cause severe
side effects.
The search for alternatives pointed out that ruthenium com-
pounds might constitute alternative promising candidates. The first
generation of ruthenium drugs, even if very successful, with two
inorganic compounds (NAMI-A and KP1019; Fig. 1) completing
Phase I clinical trials [15e17], did not lead yet to compounds in the
clinic due to limited solubility that hindered dose escalation [18]
and also short half-lifes [19]. Fuelled by these results, the area of
ruthenium conjugates has greatly expanded in the last years aiming
to overcome some of these issues and to increase the selectivity
towards cancer cells [20,21]. Several approaches based on den-
drimers and dendronized polymers [22,23], coordination-cage
[24,25], protein [26,27], nanoparticles [28,29], polymer [30e35]
and lipid-based [36] conjugates are being developed. More specif-
ically, since KP1019 has low stability in aqueous solution, especially
at physiological pH, poly(lactic acid) (PLA) nanoparticles with
Tween 80 have been prepared [37]. The proliferative studies
revealed that the nanoparticles increased the activity of KP1019 by
about 20 fold, although accompanied by a colour change from
brown to green. The authors attributed this variation to a reaction
between KP1019 and Tween 80 accompanied by a reduction of the
Ru(III) centre. One advantage of these nanoparticles was the ability
of solubilisation of KP1019 at the necessary doses for in vivo
application. In relation to NAMI-A two approaches based on the
incorporation of copolymers have been adopted. Thus, in order to
increase the cytotoxicity and cellular uptake of this drug, a NAMI-A-
copolymer conjugate based on poly(4-vinyl imidazole) and poly(-
ethylene glycol) methyl ether acrylate was designed [38]. In solu-
tion this amphiphilic block copolymer is able to self-assemble into
micelles. Overall, the cytotoxicity was increased by ca. 1.5 fold in the
cancer cells tested (ovarian cancer A2780 and Ovcar-3 and
pancreatic AsPC-1 cancer cell lines). However, one cannot neglect
the cytotoxicity induced by the poly(4-vinyl imidazole) block. The
NAMI-A micelles also seemed to impart a better antimetastatic
potential relatively to NAMI-A alone. Nanoparticles based onFig. 1. Chemical structures of KP1019 and NAMI-A.poly(lactide-co-glycolide) and poly(ethylene-glycol) have been also
successfully prepared and tested in vivo in T739 mice implanted
with lung cancer line LA795 [39]. The results showed that the
NAMI-A-loaded nanoparticles allowed a better antitumor effect,
delaying the tumour growth. Altogether, these results show the
pertinence of this area of research. In this frame, we have devel-
oped a family of polymer “ruthenium-cyclopentadienyl” conjugates
(RuPMC) as potential anticancer agents [40,41] bearing an organ-
ometallic fragment, with proved cytotoxic activity [43,44] and
adequate aqueous stability [44,45], and polylactide chains. Here,
we present a detailed study in cancer derived cell lines trying to
unravel RuPMCs’ biological activity and the possiblemode of action.
To that purpose, several biological assays namely cellular distri-
bution, analysis of cell morphological alterations, apoptosis anal-
ysis, colony formation assay, F-actin structure analysis as well as
proteomic studies were performed in different cancer cell lines
models.
2. Results and discussion
Both polymer-‘ruthenium-cyclopentadienyl’ conjugates PMC1-
PMC3 and the lowmolecular weight parental compound Ru1were
prepared as previously described [40e42] and are presented in
Fig. 2. PMC1 and PMC2 were obtained using the same protocol in
which for the synthesis of the polylactide macroligand, 2,3,4-tri-O-
benzyl-a-D-glucopyranoside was used as initiator of lactide's
polymerization catalysed by 4-dimethylaminopyridine (DMAP).
The resulting product was coupled to 2,20-bipyridine-4,40-dicar-
bonyl dichloride [40]. The synthesis of PMC3 was developed as an
alternative to this method in order to achieve full bipyridine
functionalization with polylactide (the functionalization used for
PMC1 and PMC2 was only about 75%). In the case of PMC3, the use
of 4,40-diyldimethanol-2,20-bipyridine as initiator in a DMAP cata-
lysed polymerization allowed the obtention of full bipyridine
functionalization, thus no “free” polymer is present in the final
product formulation [41]. Ru1 is the non-polymeric version of
these compounds [42] and was chosen for these studies in order to
assess the influence of the polymeric chain on the overall mode of
action of this family of compounds.
2.1. Determination of compounds IC50 concentrations
The IC50 concentration of the compounds was assessed by the
cytotoxicity assay MTT in three human cancer cell lines: A2780
ovarian, hormone dependent MCF7 and triple negative MDA-MB-
231 breast cells. The IC50 values were determined after 72 h incu-
bation with the complexes within the concentration range
10 nMe100 mM (Table 1). All the compounds showed high activity
towards the three cancer cells with low IC50 values in the micro-
molar range and, in most cases, much better than cisplatin.
2.2. Intracellular distribution of the ruthenium complexes
The intracellular distribution of the Ru complexes was per-
formed using the MCF7 cells following exposure to each ruthenium
complex for 24 h, 37 C at a concentration equivalent to their IC50
(Table S1). Cytosol, membranes, nucleus and cytoskeletal fractions
were extracted using a commercial kit (FractionPREP cell fraction-
ation kit, BioVision) following the manufacturer's protocol. The
ruthenium content in the different fractions was measured with a
Thermo XSERIES quadrupole ICP-MS instrument (Thermo Scienti-
fic) after digestion of the samples. As observed in Fig. 3, Ru was
mainly found inside the cells for all polymer-metal conjugates, in
contrast with the non-polymeric compound Ru1 that was mainly
found (Ru content) in the membrane fraction. These findings are in
Fig. 2. Compounds PMC1-PMC3 and Ru1 structures.
Table 1
In vitro cytotoxic activity of complexes PMC1ePMC3 and Ru1 against A2780 ovarian,
MCF7 and MDA-MB-231 breast cells at 72 h, 37 C, measured as the half-inhibitory
concentration (IC50).
Compound A2780 (mM) MCF7 (mM) MDA-MB-231 (mM)
Ru1 3.9± 1.3 5.9± 2.3 2.1± 0.75
PMC1 1.6± 0.6a 3.9± 1.4a 3.8± 0.6a
PMC2 0.21± 0.03 1.15± 0.25 1.03± 0.32
PMC3 3.4± 1.3b 4.1± 1.9b 2.7± 0.55b
Cisplatin 1.9± 0.1c 36± 8.0c 110± 28d
a Data from Ref. [40].
b Data from Ref. [41].
c Data from Ref. [67].
d Data from Ref. [47].
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[46e48]. Relatively to the polymer-metal conjugates, one might
expect a different cellular uptake profile due to the higher molec-
ular weight introduced by the polylactide chain that results in a
greater accumulation inside the cells. PMC3 preferentiallyFig. 3. Cellular Ru distribution in the MCF7 cells treated with the compounds PMC1-3
and Ru1 at a concentration equivalent to the IC50 found at 24 h challenge, 37 C.accumulates in the cytoskeleton fraction [41] and PMC2 is prefer-
entially retained in themembrane and cytosol fractions. Comparing
PMC1 [40] with PMC2, where the single difference is the size of the
polylactide chain, the longer polymer chain in the case of PMC1
lead to a higher accumulation in the nuclear fraction in detriment
of the cytosol uptake.2.3. Evaluation of the cell death mechanism induced by ruthenium-
based compounds
The cell death mechanism was assessed using Annexin V/Pro-
pidium iodide (AV/PI) cytometry-based assay. MCF7 cells were
incubatedwith the ruthenium compounds for 48 h at their IC50. The
results have shown that all the ruthenium-based compounds led toFig. 4. Ruthenium-based compounds potentiate apoptotic cell death. MCF7 cells were
incubated for 48 h with the ruthenium-based compounds at their IC50. Cisplatin was
used as a positive control at a concentration of 25 mM. Graphical representation of the
Annexin V/PI dotplots of cytometry data analysed using Flowing software of control,
cisplatin, PMC1-PMC3 and Ru1 compounds. Values are mean ± SD of three inde-
pendent experiences. The asterisks represent the statistically significant differences in
early (AVþ/PI-) and late (AVþ/PIþ) apoptotic cells relative to the negative control. No
statistically significant different was found in necrotic (AV-/PIþ) cells. Statistical
analysis was performed using Student's t-test. The significance was assumed for a p
value < 0.05.
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comparison to the negative control upon treatment with cisplatin
(positive control). Annexin V is a marker of early apoptosis, thus
indicating that the type of cell death induced by this compound is
apoptosis. This increase is particularly evident, and statistically
significant, for the compound Ru1 (Fig. 4). Moreover, the incuba-
tion with our compounds led to a slight increase in the percentage
of PI positive cells (A-/PIþ) for PMC2, although not reaching sta-
tistical significance, which is indicative that this drug might also
induce some necrosis as well, since PI is a marker of necrosis. The
double staining with both markers (Aþ/PIþ) suggests late
apoptosis and the percentage of double stained cells is particularly
increased with Ru1 and PMC2 compounds (Fig. 4). PMC1 did not
show any significant increase in apoptosis or necrosis in compari-
son with the negative control. Taking into account the results ob-
tained we can conclude that PMC3 and Ru1 induce apoptosis
although only reaching statistical significance with Ru1 and the
positive control cisplatin. The compound PMC2 induce apoptosis
and necrosis although the increase is not statistically significant.2.4. Morphological analysis by transmission electron microscopy
(TEM)
Electron microscopy of the cells MCF7 treated with the com-
pounds showed mitochondrial alterations in all treated cells
(Fig. 5). These ranged from edematous and disorganized mito-
chondria in compounds PMC1 and Ru1, to hypertrofic mitochon-
dria with well-developed cristae in compounds PMC2 and PMC3.
Mitochondrial hypertrophy was more developed with compound
PMC3. These results suggest that the ruthenium compounds may
have a direct effect on mitochondria, but showing distinct patterns
with different compounds. Mitochondria hypertrophy may be a
compensatory response to the increased energy demand of a
damaged cell, but with some of the compounds damaged mito-
chondria are found instead. This may indicate that these com-
pounds may have an effect upon the mitochondria impairing
energy dependent recovery mechanisms.Fig. 5. Cells treated with the ruthenium compounds. Notice the marked mitochondrial alte
with compound PMC3, and the disorganized mitochondria with compounds PMC1 and Ru2.5. Effect of PMC3 and Ru1 compounds on the cytoskeleton of
cancer cells
The cellular distribution studies suggested that PMC3 interacted
with the cytoskeleton. We have thus decided to confirm these re-
sults by F-actin immunofluorescence assay using Alexa Fluor 488®
phalloidin in the breast cancer cell lines MCF7 and MDA-MB-231.
Phalloidin is a high-affinity filamentous actin (F-actin) probe con-
jugated to the green-fluorescent Alexa Fluor® 488 dye. Further-
more, we included the parental Ru1 compound, due to the
promising properties exhibited by this drug. Our results showed
that in MCF7 control cells the integrity of the F-actin filaments are
observed with a clear plasma membrane delimitation of cells. In
contrast, in cells incubated with our compounds, cytoskeleton loses
its organization (Fig. S1). Moreover, the appearance of some dotted-
like structures inside the nuclei of cells treated with PMC3 can be
observed, and might be associated with apoptotic nucleus. In the
case of Ru1 treated cells, the staining with falloidin also evidenced
morphological alterations indicative of a process of cell death
(apoptotic bodies) that are in accordance with the results obtained
with the Annexin V/PI assay.
In the case of the untreated MDA-MB-231 breast cancer derived
cells one can observe a notable polarization with the cytoskeleton
perfectly defining the cellular shape (observed in Fig. 6). In the
same sample, several cytoskeleton extensions can be observed, cell
to cell adhesions joining cells to their neighbours. In cisplatin
treated samples the cells lose their polarity, presenting a more
rounded shape, which is in accordance with the photomicrographs
presented in Fig. 6. Moreover, cells treated with cisplatin showed
depolarization of actin filaments and the cells appear to be swollen
and bigger comparing with the untreated control. Additionally, the
cell to cell cytoskeleton extensions are reduced in cells treated with
cisplatin. PMC3 and Ru1 induce identical changes at the level of F-
actin organization: cells treated with these agents showed a
different geometry and actin depolymerization, which is not found
in untreated cells. However, and as it happens in cisplatin treated
samples, it is observed a loss of cell to cell cytoskeleton extensions
upon treatment with PMC3 and Ru1.rations in the MCF7 treated cells, particularly the marked mitochondrial hypertrophy
1. a) Control; b) PMC1; c) PMC2; d) PMC3; e) Ru1.
Fig. 6. The cytoskeleton of MDA-MB-231 cells is affected after the exposure to Ru compounds. Photomicrographs of MDA-MB-231 filamentous actin stained with Phalloidin-
AlexaFluor®488 upon exposure to the different compounds(green), with the nuclei stained with DAPI (blue). Amplification of 40x. The scale bars correspond to 25 mm. (For
interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Fig. 7. Colony formation ability of MDA-MB-231 after being exposed to the ruthenium
compounds. Untreated cells versus cells treated with ¼ of the IC50 of cisplatin, Ru1 and
PMC3 for 48 h. Results show that all the compounds statistically reduce the clonogenic
potential of this cell line. The results were obtained from at least three independent
experiments, followed by Student's T-test statistical analysis. The asterisks (*) repre-
sent the statistically different results from the negative control (p < 0.05).
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potential of cancer cells
In order to evaluate the clonogenic potential of our ruthenium-
based compounds, we evaluated their effects on survive and pro-
liferation using MDA-MB-231 breast metastatic cancer cell line for
the most promising compounds PMC3 and Ru1.
The lack of success of some chemotherapeutic regimens is based
on the fact that, even after several cycles of chemotherapy, some
cells may relapse and maintain their malignant potential. The col-
ony formation assay allows us to determine the cellular ability to
survive to the exposure of an exogenous agent for a short period
time and to produce colonies after that agent is removed, simu-
lating in vitro what actually happens during cycles of chemo-
therapy. MDA-MB-231 breast cancer derived cell line, was used as
model of the Triple Negative Breast Cancer (TNBC). TNBC comprises
cancers that are typically highly metastatic, with poorer prognosis
and for which there is still no available effective targeted therapy
[50]. Our results show that, for an exposure time of 48 h to the IC50
values of the respective compound, one week after the removal of
the agents no cells are able to grow and form colonies (data not
shown). In order to observe colonies we reduced the concentration
of the compounds up to ¼ of the IC50 values. In these conditions
colonies were observed and all the compounds reduced the clo-
nogenic ability (number of colonies) of the cells (Fig. 7). The posi-
tive control cisplatin reduced dramatically the ability of these cells
to form colonies, even at ¼ of its IC50. This is in accordance to the
literature showing that even at lower concentrations of cisplatin,
the clonogenic potential of MDA-MB-231 is extremely reduced [51].
The results presented here are very exciting regarding the possible
application of these new ruthenium compounds in chemotherapy,
since the number of cells that may relapse might be significantly
reduced.
These results open exciting possibilities regarding the applica-
tion of the compounds in chemotherapy: since chemotherapeutic
regimens based on cisplatin usually raise severe side effects, our
in vitro results may indicate that wemay be able to obtain the same
results of cisplatin using lower doses of these ruthenium-basedagents.2.7. Uptake of PMC3 and Ru1 complexes in sensitive and resistant
cancer cells
One major limitation in current chemotherapy is the acquired
resistance that cancer cells might develop. Cancer patients are
usually treated by repeated cycles of chemotherapy and, for many,
the disease relapses in the medium term. A good example to un-
derline the importance of cisplatin treatment and resistance is the
Fig. 8. Platinum and ruthenium uptake in ovarian cancer cells.
Table 3
Accumulation difference between the A2780 and A2780cis cells (%).
Tested concentration Compound Accumulation difference [%] SD
5 mM Cisplatin 40.1 4.5
20 mM PMC3 24.4 7.6
20 mM Ru1 93.7 1.1
T. Moreira et al. / European Journal of Medicinal Chemistry 168 (2019) 373e384378case of ovarian cancer. Currently, the standard treatment for
advanced ovarian cancer involves surgery followed by chemo-
therapy (first line: platinum-based drugs). Although this regimen
initially results in a response rate of 40e60% in patients with
advanced disease, most relapse after 18 months due to the
appearance of drug-resistant tumours. Drug resistance accounts for
the treatment failure and death in more than 90% of ovarian cancer
in patients with advanced disease [52]. Various multidrug
resistance-associated proteins (MRPs) belonging to the ABCC (ATP
binding cassette subfamily C) subfamily of ABC efflux transporters
have been implicated to mediate resistance to platinum com-
pounds [53]. There is now significant evidence that MRP2/ABCC2
has a major impact in the acquisition of the resistant phenotype
and its reversal. Particularly in ovarian cancer, in vitro studies on
A2780 and A2780cis revealed an overexpression of MRP2 in the
cells [54,55] and silencing of MRP2 expression and function proved
to modulate cisplatin accumulation and resistance [56e58]. Finally,
the use of ABCC2 specific inhibitors allowed to reversed cisplatin
resistance [59,60]. Thus, we wanted to verify if these new ruthe-
nium derivatives were a MRP2 substrate. For that, flow cytometry
was used to quantify their intracellular accumulation in WT vs.
MRP2-expressing cells. We expect to have a high level of accu-
mulation of the drug in the WT cells and MRP2 cells if the com-
pound is not transported byMRP2. If the compound is a substrate of
MRP2 its accumulation level will be lower than in WT. A 2-fold
accumulation difference is considered expressive to protein-
mediated efflux [61].
Using the LSR Fortessa and LSRII 4 lasers cytometers (BD Bio-
Sciences, San Jose, CA, USA), we opened all channels for the
detection of the compounds, paying special attention to the violet
channel. However, as expected from the fluorescence spectra of the
compounds (they all absorb light with peaks around 260 (±15) nm;
the fluorescence excitation spectra of the compounds show that
they are all fluorescence with an emission at around 300 (±10) nm),
we could not detect any fluorescence related to the compounds.
Indeed, for both equipment, the lowest excitation wavelength is
355 nm (violet), therefore not suitable for the excitation of these
ruthenium derivatives. For emission too, the filters make only
possible the detection of light above 350 nm. Given this technical
impediment to directly screen MRP2-mediated transport, we
evaluated the uptake of the compounds in sensitive and cisplatin-
resistant cells using mass cytometry coupled to cytometry.
In mass cytometry, the channels for the acquisition of all
ruthenium isotopes (96e102 atomic weights) were opened, but
during analysis we saw that the accumulation level of ruthenium
was similar regardless of the chosen isotope. Therefore, the Ru102
isotope was chosen for analysis (an example of the analysis is given
in Fig. S2). We also determined the uptake of platinum using the Pt
194 tag.
We started by verifying the level of accumulation of cisplatin
and ruthenium in the sensitive and resistant cell lines (A2780 and
A2780cis) after 20min treatment with 20 mM of the PMCs or 5 mM
of cisplatin. The results are given in Table 2 and represented inTable 2
Ruthenium and platinum uptake in ovarian cells. A2780 cells are sensitive to cisplatin, w
5 mM cisplatin or 20 mM of each ruthenium compound.
Tested concentration Compound A2780
Mean SD
na C0 0.6 0.1
5 mM Cisplatin 27.1 5.8
20 mM PMC3 94.1 14.2
20 mM Ru1 215.5 28.9
For cisplatin: measurement of the abundance of Pt194 isotope (GeoMean, [ua]); For rutheFig. 8.
Our data shows that intracellular ruthenium accumulation
varies greatly with the derivatives tested. The accumulation of the
ruthenium derivatives in sensitive cells is greater than in resistant
ovarian cancer cells. This result is in accordancewith literature data
that points out to the fact that in multidrug resistant cells many
mechanisms of resistance are triggered (including impaired influx,
efflux, DNA repair mechanisms, etc …). The accumulation in the
sensitive cells is an interesting aspect in the development of new
drugs targeting to overcome drug resistance since an efficient
accumulation in the first place could mean a better maintenance of
the bioactive concentration of the drug in the cells, which might
make them less susceptible to gain resistance. To avoid drug
resistance due to insufficient accumulation of the drug in the cells,
the aim would be to find a molecule that accumulates to the same
level in both sensitive and resistant cells [62]. To see which one of
our compounds is most efficient, we have calculated the differences
of accumulation in sensitive and resistant cells (given in Table 3 and
Fig. 9). Using the formula A2780A2780cisA2780  100, where A2780 rep-
resents the accumulation level in the cisplatin-sensitive cells and
A2780cis that of cisplatin-resistant cells. The difference in the
accumulation of the metal tag in the sensitive cells was determined
and compared to resistant cells. Our goal is to find compounds with
the smallest difference e the resistant cells should accumulate
similar levels of the drug as the sensitive cells. As shownTable 3 and
Fig. 9, the most promising candidate is the ruthenium-polymer
conjugate PMC3. This compound is especially promising since the
difference in the accumulation between sensitive and resistant cellshile A2780cis are resistant to treatment. All cells (except controls) were treated with
A2780cis
Corrected Mean SD Corrected
0.0 0.3 0.0 0.0
17.1 (CO¼ 10) 24.6 4.3 10.3
93.5 71.0 18.3 70.6
214.9 13.9 4.3 13.5
nium compounds: measurement of the abundance of Ru102 isotope (GeoMean, [ua]).
Fig. 9. Difference of accumulation of drugs (%) between sensitive and resistant ovarian
cancer cells.
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to 40% difference in the accumulation of platinum after treatment
with cisplatin). The lower accumulation level of ruthenium after
20min treatment with PMC3 relatively to Ru1may be explained by
a slower cell uptakemechanism since after 24 h this is no longer the
case (see data from the intracellular distribution studies). From this
perspective, PMC3 might be a good candidate for a future drug
since ruthenium accumulation levels after a 20-min treatment with
20 mM of the drug in A2780cis cells is similar to that in A2780 cells.
This means that PMC3 accumulates efficiently in both sensitive and
resistant ovarian cancer cells.
2.8. Proteomic study in MDA-MB-231 cells treated with PMC3 and
Ru1
Taking into consideration the phenotypic changes observed on
the cells treated with Ru1 and PMC3, we performed a bottom-up
proteomic approach using a GeLC-MS/MS strategy (protein sam-
ples included in polyacrylamide gel without fractionation were
analysed by nanoLC-MS/MS after in-gel digestion) combined to two
label-free quantitative methods based on Spectral Counting (SC)
and Average Precursor Intensity (API) to search for the possible
target-related proteins of both compounds.
A total of 354 proteins in 264 clusters were identified in MDA-
MB-231 cells (control and cells treated with PMC3 and Ru1)
(Table S1.1-4). Functional analysis of the 354 proteins identified,
corresponding to 298 unique gene names, was performed using
PANTHER classification system (Fig. S3). Cellular component anal-
ysis shows that the majority of proteins are from the cellular frac-
tion (39.8% of cellular components hits), and 31.9% and 21.1% of
proteins are from organelles and macromolecular complexes,
respectively. The remaining proteins belong to different cell com-
partments as membrane (5%), extracellular region (1.5%), cell
junction (0.6%) or synapses (0.3%). Molecular function analysis
revealed that most of the proteins identified had binding activity
(46.3%) such as chaperones or nucleic acid binding proteins (33.6%),
followed by those with catalytic activity as transferases, hydrolases
or oxidoreductase enzymes (28.7%). Several proteins were also
identified to have structural molecule activity (11.9%).
From label-free quantitative proteomic experiments, out of 153
differential proteins for Ru1 or PMC3 vs control were characterized
(Table S2.1). For more robustness, we retained only the 112 non-
redundant proteins quantified by the two independent quantita-
tive methods (SC and API). In total, 61 and 51 unique accession
numbers were characterized differently (p< 0.05, fold change >2)
between Ru1 or PMC3 treated cells with the control cells, respec-
tively (Table S2.2 and S2.3). Comparison between control cells and
those treated with Ru1 shows that 21 proteins are more abundantin Ru1 treated condition and 40 proteins are less abundant. For cells
treatedwith PMC3, 34 proteins are more abundant in PMC3 treated
condition and 17 proteins are less abundant.
For cells treated with PMC3, the molecular functions analysis
using PANTHER revealed that majority of the less abundant pro-
teins were involved in binding (55.60%), and especially in nucleic
acid binding as transcription factors, while proteins with higher
abundance belong to the catalytic activity (55.60%) and binding
(25.90%) protein classes. For cells treated with Ru1, as observed for
PMC3, a high percentage of the less abundant proteins in Ru1
treated cells were linked to binding protein class (53.70%), in which
41% are nucleic acid binding proteins, and the majority of the more
abundant proteins were involved in catalytic activity (50%) and
binding (27.80%).
Based on STRING proteineprotein interaction predictions, an
association network of the proteins, which have their expression
modified due to the treatment with PMC3 or Ru1, was created
(Figs. S4 and S5). We were especially interested on those proteins
related to the observed phenotypic alterations, such as those
involved in the cytoskeleton dynamics, mitochondrial and involved
in apoptosis. This bioinformatics analysis indicated that an impor-
tant group of proteins identified in PMC3 were related to cellular
cytoskeleton dynamics, cell stress, namely endothelial reticulum
stress, cell cycle and apoptosis. A closer analysis leads us to
postulate that proteins that regulate the microtubule dynamics are
the target of PMC3 which might be associated to the fact that this
compound inhibit proliferation that might be due to an arrest of
mitosis. Indeed, microtubules dynamic are pivotal for mitosis
occurrence as they are the crucial constituents of the mitotic
spindle essential for chromosomes separation during mitosis [63].
Moreover, at the beginning of mitosis (prophase, prom-
etaphase), several cellular components are disassembled, including
the nuclear envelope, the nuclear lamina and the nuclear pore
complexes. The nuclear breakdown is necessary to allow the
mitotic spindle to interact with the kinetochores of the condensed
chromosomes [63]. Here we also gathered results supporting again
the role of PMC3 in cell cycle arrest, as we found an upregulation of
Prelamin-A/C (LMNA), a mitosis-promoting factor, that causes
depolymerization of the lamin intermediate filaments, and the
downregulation of lamina-associated polypeptide 2 (TMPO) pro-
tein involved in the transport to the plus end of the microtubules,
assembly of the nuclear lamina and maintenance of individual
mitotic chromosomes dispersed in the cytoplasm following nuclear
envelope disassembly [63]. Moreover, there is also experimental
evidence of chromatin condensation at the cells treated with PMC3
(Fig. S1 and Fig. 5). These evidences might be related also to the
apoptosis process, where there is nucleic acid degradation and in
which the nuclear lamina is disassembled in an early stage. This
sequence of events induces endoplasmic reticulum stress leading to
an increase of the heat shock proteins and chaperones as a response
for the cell stress [64]. We can hypothesise that since the cyto-
skeleton has lost its organization (as also observed on our experi-
mental data), the proteins might no longer be capable to move
along from the ER to their destiny.
The results from this bioinformatics analysis indicated the
groups of proteins deregulated after treatment with Ru1 are the
same as PMC3, i.e., cellular cytoskeleton dynamics, cell stress, cell
cycle and apoptosis. However, in the case of Ru1, there are several
proteins related to cell adhesion and migration that are down-
regulated, what is in accordance with the phenotypic alterations
observed, namely changes in the actin organization and loss of cell
to cell cytoskeleton extensions. A closer analysis on the proteins
lead us to postulate that proteins that regulate the actin dynamics
are the target of Ru1whichmight explainwhy Ru1 induce cell cycle
arrest at G2/M phase. Actin cytoskeletal organization is important
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proteins, is a member of the actin depolymerizing factor (ADF)/
cofilin family that is required for the regulation of actin dynamics.
Cofilin regulates the dynamics of the actomyosin-based contractile
ring being essential for cell division during mitosis [63]. Interest-
ingly, loss of cofilin expression leads to G2/M phase arrest and to
the formation of multinucleate cells, what is in accordancewith our
observations in Fig. 6.
Overall, the proteomic study correlated well with the pheno-
typic alterations observed such as mitochondrial hypertrophy,
disorganization of cytoskeleton, cell cycle arrest and apoptosis.
3. Conclusion
Taking into consideration all the results obtained from the
different biological studies that have been performed, the polymer-
ruthenium conjugate PMC3 is doubtless the most promising met-
allodrug that might constitute a lead molecule to pursuit in the
future. This compound has shown good cytotoxic activity towards
three cancer cell lines harbouring different genetic alterations. All
compounds induce inhibition of proliferation and apoptosis,
interfering with mitochondria and with cytoskeleton in the MCF7
cancer cell line. PMC3 also highly reduces the colony formation
potential of MDA-MB-231 breast cancer cells. A closer analysis by a
bottom-up proteomic approach of the proteins involved in the
phenotypic changes observed, lead us to postulate that those pro-
teins responsible for the regulation of the microtubule dynamics
are the target of PMC3. Such a mechanism seams similar to that
observed for the drug Paclitaxel that suppresses microtubule dy-
namics, causing the block of mitotic activity leading to apoptosis
[65]. These results place PMC3 within a new class of drugs called
migrastatic agents [66], i.e. anti-metastatic and anti-invasion drugs
which targets are actin polymerization and contractility.
Importantly, PMC3 might not be subject of protein-mediated
efflux from A2780cis ovarian human cancer cells, contrarily to
Ru1. This result is of upmost importance since resistance to treat-
ment is a major threat for the success of chemotherapy.
Summing up, we have disclosed important hints on the mech-
anism of action of new ruthenium(II) compounds which might be
of potential interest for the therapy of metastatic and resistant
cancers. PMC3 seem to be a lead molecule to pursuit in the future,
and the potential of this compound might even be improved by its
functionalization with biomolecules of interest in order to induce a
receptor-mediated internalization towards a dual passive and
active targeting.
4. Experimental section
4.1. Compounds under study
All syntheses were carried out under dinitrogen atmosphere
using current Schlenk techniques and the solvents used were dried
using standard methods. All compounds were synthesized using
protocols recently reported by us (PMC1-2 [40], PMC3 [41], Ru1
[42]).
4.2. Biological activity evaluation
4.2.1. Cell lines
The MDCKII (Madin-Darby Canine Kidney II) WT and MRP2 cell
lines were kindly offered by Pr. Piet Borst, (The Netherlands Cancer
Institute, Amsterdam, Netherlands). They are epithelial kidney
cells, and the MDCKII-MRP2 cell line was generated by transfection
with a pCMV-cMOAT retrovirus (clone 17; MDCKII-MOAT17) [70].
The A2780 and A2780cis are ovarian cancer cell lines, purchasedfrom Sigma Aldrich (for flow cytometry studies) or to ATCC (cyto-
toxicity evaluation). Cisplatin resistant cell line A2780cis (Sigma no.
93112517) is derived fromA2780 cell line and it has been developed
by chronic exposure of the parent cisplatin-sensitive A2780 cell line
(Sigma no. 93112519) to increasing concentrations of cisplatin.
A2780cis is cross-resistant to other drugs such as melphalan and
adriamycin. An increased ability to repair DNA damage as well as
cytogenetic abnormalities has been observed. The MCF7 and MDA-
MB-231 breast cancer human tumour cell lines were purchased to
ATCC.
4.2.2. Cell culture
MDCKII cells were cultured in Dulbecco's modified Eagles' me-
dium (DMEM high glucose) supplemented with 10% fetal bovine
serum (FBS), 1% penicillin/streptomycin, without selection for the
MRP2-transfected cell line. A2780 and A2780cis cell lines were
cultured in RPMI medium with 10% FBS and 1% penicillin/strepto-
mycin. Cisplatin was added every 2e3 passages to the media to the
resistant cell line, in order to retain its resistance. MCF7 and MDA-
MB-231 breast cancer human tumour cell lines were grown in cell
culture flasks in a 5% CO2 incubator at 37 C with humidified at-
mosphere (Heraeus, Germany). The culture media DMEM with
Glutamax I was supplemented with 10% FBS (fetal bovine serum)
and 1% penicillin/streptomycin. All the cells were adherent in
monolayers and, upon confluence, were harvested by digestion
with trypsin-EDTA (Gibco).
4.2.3. Cell viability assays in human tumour cell lines
The cytotoxic activity of the Ru complexes against the tumour
cells was assessed using the MTT assay based on the reduction of
the tetrazolium dye to formazan. For this purpose, cells were
seeded into 96-well plates at a density of approx. 10 103/200 mL
medium and incubated for 24 h (37 C/5% CO2) to adhere. Com-
pounds were dissolved in DMSO and then in medium and added to
the cells in serial dilutions in the range 10 nMe100 mM. At the end
of incubation time, the treatment solutionwas discarded and aMTT
solution (0.5 mg/200mL PBS) was added to each well. After 3 h at
37 C/5% CO2, the solution was removed and the formazan crystals
formed inside the cells were dissolved in 200 mL DMSO. The
absorbance values were measured at 570 nm using an ELISA reader
(PowerWave Xs, Bio-Tek Instruments, Winooski, VT, USA). The IC50
values were determined by nonlinear regression using GraphPad
Prism software version 4.0.
4.2.4. Cellular uptake by ICP-MS analysis
For the cellular uptake experiments, MCF7 cells (ca. 106 cells/
5mL medium) were exposed to the complexes at a concentration
equivalent to their IC50 values found for 24 h challenge, 37 C. After
incubation cells were thenwashed with ice-cold PBS and treated in
order to obtain a cellular pellet [67]. The cytosol, membrane/par-
ticulate, cytoskeletal and nuclear fractions were extracted using a
FractionPREPTM, cell fractionation kit (BioVision, USA) and per-
formed according to the manufacturer's protocol. The Ru (101Ru)
content in each fraction was measured by a Thermo X-Series
Quadrupole ICP-MS (Thermo Scientific) after digestion of the
samples and using the same procedure previously described [67].
4.2.5. Cell death measurement by flow cytometry, Annexin V/PI
assay
AV/PI assay is widely used to determine cellular apoptosis as it
allows to differentiate between apoptotic, or necrotic cells through
differences in plasma membrane integrity and permeability [49].
After 48 h of treatment with the compounds both suspended and
attached cells were collected and washed in 1x PBS. 1 106 cells
were resuspended in 100 mL 1x binding buffer and incubated with
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USA) and 10 mL 50 mg/mL PI for 15min in the dark. Samples were
analysed in an Epics® XLTM (Beckman Coulter) cytometer, equip-
ped with an argon-ion laser emitting a 488-nm beam at 15mW.
Monoparametric detection of red fluorescence was performed us-
ing FL-4 (488/675 nm) and detection of green fluorescence was
performed using FL-1 (488/525 nm). 20 000 cells were analysed per
sample and data analysed using FlowJo software (version 7.6, Tree
Star Inc., Ashland, OR, USA).
4.2.6. Morphological analysis by transmission electron microscopy
TEM
MCF7 cells at approximately 70% confluence were treated with
all the complexes at a concentration equivalent to their IC50 values
at 24 h challenge, 37 C. Untreated cells were used as controls. After
incubation, the culture medium was discarded and replaced by
5mL of primary fixative consisting of 3% glutaraldehyde in 0.1M
sodium cacodylate buffer pH 7.3. Following primary fixation for
2 h at 4 C and wash in the cacodylate buffer (5mL), cells were
scrapped, pelleted and embedded in 2% agar for further processing.
Samples were further fixed for 3 h in 1% osmium tetroxide in 0.1M
sodium cacodylate buffer pH 7.3. Then, samples were washed in
0.1M acetate buffer, pH 5.0 and fixed in 0.5% uranyl acetate in the
same buffer for 1 h. Dehydration was carried out with increasing
concentrations of ethanol. After passing through propylene oxide,
samples were embedded in Epon-Araldite, using SPI-Pon as an
Epon 812 substitute. Thin sections were made with glass or dia-
mond knives and stained with 2% aqueous uranyl acetate and
Reynold's lead citrate. The stained sections were analysed and
photographed in a JEOL 1200-EX electron microscope.
4.2.7. Effect of compounds PMC3 and Ru1 on cytoskeleton, F-actin
staining
For visualization of actin fibres, cells were seeded in cover-slips
allowing the cell attachment overnight. Cells where then treated
with the IC50 of the compounds for 48 h. After the incubation time
the cells wherewashed with warm PBS and fixed for 20min in 2.5%
of Glutaraldehyde. Furthermore, cells where washed with PBS and
permeabilized with 0.1% of Triton X-100 for 5min. After another
washing step cells were incubated in the dark with Alexa Fluor®
488 phalloidin for 20min. For fluorescence microscope visualiza-
tion in inverted microscope (Olympus IX71), the excess of fluo-
rophore was washed with PBS and coverslips where mounted with
vectashield mounting medium.
4.2.8. Colony formation assay
MDA-MB-231 were seeded in 6-well plates at 400 cells/mL. 24 h
after plating, cells were incubated with ¼ of the IC50 value of the
different compounds. 48 h after the incubation, old medium was
removed and cells were incubated with fresh medium. Medium
was renewed every 3 days. 7 days after removing the treatments,
cells were washed with PBS and incubated in a solution of glutar-
aldehyde (6% (v/v)) with crystal violet (0.5% (w/v)) for at least half
an hour. The plate was washed with fresh water and left air dry.
Colonies were counted manually. The negative control was incu-
bated with the correspondent volume of DMSO used in the sol-
ubilisation of the compounds (vehicle), and the final concentration
of DMSO per well did not exceed 0.1%.
4.2.9. Fluorescence tests and flow-cytometry
4.2.9.1. Fluorescence spectra. To determine the fluorescence emis-
sion spectra of the compounds, they were prepared at 10 mM in a
mixture of DMSO and distilled water (1:10). Using a TECAN 50000
equipment, we first determined the absorption spectra, then the
fluorescence excitation wavelength and the fluorescence emissionspectra.
4.2.9.2. Flow cytometry. MDCKIIWTandMRP2 cells were seeded at
a density of 105 cells/well into 24-well culture plates. After a 48-h
incubation period, they were exposed to different concentrations
of compounds for 30min at 37 C, and then theywere incubated for
30min at 37 C in the presence of 10 mM of each compound as
substrate. After treatment, the cells were then washed with phos-
phate buffer saline and trypsinized. The intracellular fluorescence
was monitored with LSR Fortessa and LSRII 4 lasers cytometers (BD
Biosciences, San Jose, CA, USA), using the fluorescence channels,
and at least 5000 events were collected.
4.2.9.3. Evaluation of the uptake of the compounds in single cells by
mass cytometry. In this technique, cells are stained with a stable
isotope tag and injected into a mass spectrometer coupled with a
cytometer. Cells are vaporized, atomized and ionized in a (high
temperature) Inductively Coupled Plasma (ICP), and the atomic
composition of each cell (including metal tags) is measured by time
of flight mass spectrometry (TOF-MS), generating distinct mass
spectra of each cell. The mass cytometer is also capable of
measuring heavy elements naturally present or introduced into a
cell, such as iodine and platinum [68]. Reporter ions are quantified
by time of flight mass spectrometry. Data is parsed into single cell
events and converted to a flow cytometry standard (FCS) file for
analysis [69]. We evaluated the transport of ruthenium derivatives
in MDCKII WT and MRP2 cells and in ovarian cancer cells sensitive
and resistant to cisplatin A2780 and A2780cis. Cells were seeded in
6-wells plates for 48 h to reach a density of ~1 million cells/mL.
Cells were treated for 15min with 20 mM of each compound. We
used 5 mM of cisplatin to verify the different accumulation levels in
each cell line. After treatment, cells werewashedwith PBS and then
fixed in 1mL PFA 4%. Next day, the supernatant was discarded and
wemarked DNA of the cells with iridium. Thenwe carefully washed
the cells for remaining traces of metals with MaxPar Water. Cells
were analysed using a cyTOF mass cytometer (DVS Sciences Inc,
Markham, ON, Canada). A minimum of 5 104 events were
collected for each sample. Channels for all ruthenium isotopes were
opened (atomic masses 96, 98e102, 104), as well as the channels
for iridium (atomic masses 191 and 193) and platinum (atomic
masses 190, 192, 194e196, 198). Data in FCS format was analysed
using the FlowJo v10.0.7 software - GeoMean Ir191, Ir193, Pt194, Ru102.
4.3. Data analysis
All tests were done in duplicates and statistical analysis was
conducted using specialized software. Flow-cytometry analysis was
done using the FlowJo V.10.0.7 software. Statistical analysis was
done using Excel.
4.4. Proteomic study
4.4.1. Collection and preparation of cells
MDA-MB-231 cells were cultivated as described previously. For
each condition (PMC3, Ru1, control), we performed two biological
replicates (pool 1 and 2). The cells were non-enzymatically har-
vested using a 0.48mM PBS-EDTA solution (4 C). Upon detach-
ment, the cells were collected and centrifuged at 800g for 8min.
The pellets were washed with PBS and centrifuged again. This
washing step was repeated three times. The pellets were kept
at 80 C until needed for further studies.
4.4.2. Sample preparation for MS analysis
The cells were sonicated in a lysis buffer containing 50mM Tris-
HCl, pH 7.5, 150mM NaCl, 1% NP-40, 1/10 phosphatase inhibitor
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(P2714, Sigma) and centrifuged 10min, 4 C at 10,000g. The su-
pernatant protein concentrations were determined using a BC
Protein Assay (Interchim, Montlucon Cedex, France), using bovine
serum albumin (Sigma-Aldrich, Saint Quentin Fallavier, France) as
the standard. SDS-PAGE (minigel 8.3 6 cm x 1mm) was carried
out to include the proteins within a 10% polyacrylamide gel,
without fractionation (50 V, 20min), with a protein load of 37 mg
total protein per lane. The gel was then stained with Coomassie
blue (overnight at room temperature (RT) with agitation). The
whole lane (one band) was excised for tryptic digestion and mass
spectrometry (MS) analysis.
Gel pieces were washed in a solution of water:acetonitrile (1:1,
5min) followed by 100% acetonitrile (10min). Reduction and
cysteine alkylation were performed by successive incubations with
10mM dithiothreitol in 50mM NH4HCO3 (30min, 56 C), then
55mM iodoacetamide in 50mM NH4HCO3 (20min, RT, in dark).
Pieces were then incubated with 50mM NH4HCO3 and acetonitrile
(1:1, 10min) followed by acetonitrile (15min). Proteolytic digestion
was carried out overnight using 25mM NH4HCO3 with 12.5 ng/ml
Trypsin (Sequencing grade, Roche diagnostics, Paris, France).
Resultant peptides were extracted by incubation in 5% formic acid
(sonicated) with the supernatant removed and saved, followed by
incubation in acetonitrile and 1% formic acid (1:1, 10min) and a
final incubation with acetonitrile (5min), again supernatant was
removed and saved. These two peptide extractions were pooled
and dried using a SPD1010 SpeedVac system (Thermosavant,
Thermofisher Scientific, Bremen, Germany) and the peptide
mixture was analysed by MS.
4.4.3. NanoLC-MS/MS analysis
After in-gel digestion by trypsin, peptide mixtures were ana-
lysed by on-line nanoflow liquid chromatography tandem high
resolution mass spectrometry (nanoLC-MS/MS). For each biological
sample (pool 1 and 2) and for each condition (PMC3, Ru1 and
control), we performed four technical replicates. All experiments
were performed on a dual linear ion trap Fourier Transform Mass
Spectrometer LTQ Orbitrap Velos (Thermo Fisher Scientific, Bre-
men, Germany) coupled to an Ultimate® 3000 RSLC Ultra High
Pressure Liquid Chromatographer (Thermo Fisher Scientific, Bre-
men, Germany) controlled by Chromeleon Software (version 6.8
SR11). Samples were desalted and concentrated for 10min at 5 mL/
min on an LCPackings trap column (Acclaim PepMap 100C18, 75 mm
inner diameter x 2 cm long, 3 mm particles, 100 Å pores). The pep-
tide separations were conducted using a LCPackings nano-column
(Acclaim PepMap C18, 75 mm inner diameter x 50 cm long, 2 mm
particles,100 Å pores) at 300 nL/min by applying gradient consisted
of 4e60% B during 180min. Mobile phases consisted of (A) 0.1%
formic acid, 97.9% water, 2% acetonitrile (v/v/v) and (B) 0.1% formic
acid, 15.9% water, 84% acetonitrile (v/v/v).
Data were acquired in positive ion mode and in data-dependent
mode to automatically switch between high resolution full-scanMS
spectra (R 60 000) in the 300e1800 m/z mass range and MS/MS
spectra. The 20 most intense peptide ions with charge states  2
were sequentially isolated and fragmented in the high pressure
linear ion trap using CID mode (collision energy 35%, activation
time 10ms, Qz 0.25). Dynamic exclusion was activated during 30 s
with a repeat count of 1. The lock mass was enabled for accurate
mass measurements. Polydimethylcyclosiloxane (m/z,
445.1200025, (Si(CH3)2O)6) ion was used for internal recalibration
of the mass spectra.
4.4.4. Protein identification and validation
MS/MS ion searches were performed using Mascot search en-
gine version 2.3.02 (Matrix Science, London, UK) via ProteomeDiscoverer 2.1 software (ThermoFisher Scientific, Bremen, Ger-
many) against SWISSPROT_mammalian databases (144 541 entries,
download 01/01/2017). The search parameters included trypsin as a
protease with two allowed missed cleavages and carbamidome-
thylcysteine, methionine oxidation and acetylation of N-term pro-
tein as variable modifications. The tolerance of the ions was set to
5 ppm for parent and 0.8 Da for-fragment ion matches. Mascot re-
sults obtained from the target and decoy databases searches were
subjected to Scaffold software (v 4.8.4, Proteome Software, Port-
land, USA) using the protein cluster analysis option (assemble
proteins into clusters based on shared peptide evidence). Peptide
and proteins identifications were accepted if they could be estab-
lished at greater than 95.0% probability as specified by the Peptide
Prophet algorithm and by the Protein Prophet algorithm, respec-
tively [71,72]. Protein identifications were accepted if they con-
tained at least two identified peptide. The False Discovery Rate
(FDR) was < 0.01%.
4.4.5. Label-free protein quantifications
For comparative analyses, we employed Scaffold Qþ software
(version 4.8.4, Proteome Software, Portland, USA) to apply two
independent quantitative methods: 1) the Spectral Counting which
counts and compares the number of fragment spectra identifying
peptides of a given protein; 2) the Average Precursor Intensity
which measures and compares the mass spectrometric signal in-
tensity of peptide precursor ions belonging to a particular protein.
Quantificationwas performed using the “Weighed Spectra”method
where the weight is a measure of how much a spectrum is shared
by other proteins. Thus, numbers of Normalized Weighed Spectra
(NWS) were tabulated using experiment wide protein clustering.
The reproducibility linked directly to the nanoLC-MS methodology
was evaluated by the coefficient of variance (CV) for each condition
(pool1-2 for PMC3 or Ru1 vs control) considering 4 technical rep-
licates and for each protein group (Table S2.4). Significance be-
tween treatments and control was determined using statistical
tests within Scaffold software; t-tests for SC and API quantification,
where p< 0.05 was considered significant. Limits of an average
normalized weighted spectra (NWS) of 5 and fold change/ratio of
 2 were included to increase validity of any comparisons made.
4.4.6. Gene ontology, localisation and network analysis
Gene symbols (human orthologs) were mapped for all protein
identifications and analysed using two different bioinformatics
tools. In order to estimate which cell compartments/functions are
mainly represented by the identified proteins, a systems biology
analysis was performed using PANTHER [73] (Protein ANalysis
THrough Evolutionary Relationships) Classification System (v 13.1
released 2018-02-03, www.pantherdb.org).Homo sapiens organism
was selected to maximise classifications. Predicted protein-protein
associations were evaluated using STRING [74] database (v 10.5,
www.string-db.org) on lists of differential proteins characterized
for PMC3 or Ru1 conditions with control. Networks were extracted
for proteins presenting more or less abundant in PMC3 or Ru1
conditions.
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